Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
Journal of Neurogastroenterology and Motility
;
: 141-151, 2014.
Artigo
em Inglês
| WPRIM
| ID: wpr-87491
ABSTRACT
Irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs. Related to the heterogeneity of pathogenesis that underlie these disorders and the failure of symptoms to reliably predict underlying pathophysiology, traditional therapies provide relief to only a subset of affected individuals. The evidence surrounding new and emerging pharmacologic treatments, which include both luminally and systemically acting drugs, is discussed here. These include agents such as lubiprostone, bile acid modulations, guanylate cyclase-C receptor agonists, serotonin receptor modulators and herbal therapies.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Qualidade de Vida
/
Características da População
/
Bile
/
Custos de Cuidados de Saúde
/
Agonistas do Receptor de Serotonina
/
Constipação Intestinal
/
Síndrome do Intestino Irritável
/
Laxantes
/
Lubiprostona
Tipo de estudo:
Estudo prognóstico
Idioma:
Inglês
Revista:
Journal of Neurogastroenterology and Motility
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS